Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STR-P005 in Relapsed/Refractory Autoimmune Diseases
NCT07655453Phase 1Not yet recruiting
- Sponsor
- Starna Therapeutics
- Start
- Aug 2026
- Primary completion
- Jul 2027
01
Overview
Phase 1, open-label, single-arm trial of STR-P005 in autoimmune disease, sponsored by Starna Therapeutics. Primary endpoint: Adverse Events at 24 months. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
STR-P005
03
Conditions
autoimmune disease
Beyond the preview
Go deeper on NCT07655453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07655453.